Cargando…
Metabolism and Pharmacokinetic Drug–Drug Interaction Profile of Vericiguat, A Soluble Guanylate Cyclase Stimulator: Results From Preclinical and Phase I Healthy Volunteer Studies
BACKGROUND: Vericiguat is a stimulator of soluble guanylate cyclase currently under investigation as a first-in-class therapy for worsening chronic heart failure (NCT02861534). Patients with heart failure often require polypharmacy because of comorbidities. Hence, understanding the clearance mechani...
Autores principales: | Boettcher, Michael, Gerisch, Michael, Lobmeyer, Maximilian, Besche, Nina, Thomas, Dirk, Gerrits, Mireille, Lemmen, Julia, Mueck, Wolfgang, Radtke, Martin, Becker, Corina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7658073/ https://www.ncbi.nlm.nih.gov/pubmed/32458378 http://dx.doi.org/10.1007/s40262-020-00895-x |
Ejemplares similares
-
Soluble Guanylate Cyclase Stimulator Vericiguat Enhances Long-Term Memory in Rats without Altering Cerebral Blood Volume
por: Nelissen, Ellis, et al.
Publicado: (2021) -
Pharmacodynamic and Pharmacokinetic Interaction Profile of Vericiguat: Results from Three Randomized Phase I Studies in Healthy Volunteers
por: Boettcher, Michael, et al.
Publicado: (2020) -
Stimulation of soluble guanylate cyclase by vericiguat reduces skeletal muscle atrophy of mice following chemotherapy
por: Hu, Bo-ang, et al.
Publicado: (2023) -
Pharmacokinetics of the soluble guanylate cyclase stimulator riociguat in individuals with renal impairment
por: Frey, Reiner, et al.
Publicado: (2013) -
Pharmacokinetics of the soluble guanylate cyclase stimulator riociguat in individuals with hepatic impairment
por: Frey, Reiner, et al.
Publicado: (2013)